There are 412 resources available
262TiP - PROVIDENCE: A prospective, non-interventional study examining real-world clinical and patient-reported outcome (PRO) data in patients (pts) with HER2-positive or HER2-low unresectable or metastatic breast cancer (mBC) treated with trastuzumab deruxtecan
Presenter: Manfred Welslau
Session: Lunch and Poster Display session
263TiP - Implementing geriatric assessment for dose optimization of CDK 4/6-inhibitors in older breast cancer patients (IMPORTANT trial): A pragmatic randomized-controlled trial
Presenter: Antonis Valachis
Session: Lunch and Poster Display session
264TiP - TACTIVE-K: Phase Ib/II study of vepdegestrant, a proteolysis targeting chimera (PROTAC) estrogen receptor (ER) degrader, in combination with PF-07220060, a cyclin-dependent kinase (CDK)4 inhibitor, in ER+/human epidermal growth factor receptor 2 (HER2)- advanced breast cancer
Presenter: Melinda Telli
Session: Lunch and Poster Display session
265TiP - SOLTI-2201 ACROSS-TROP2 trial: A phase II study to identify predictive biomarkers of sacituzumab govitecan benefit and to understand resistance mechanisms in HR+/HER2- advanced or metastatic breast cancer
Presenter: Eva Ciruelos
Session: Lunch and Poster Display session
272P - Evaluating a digital tool for supporting people affected by breast cancer: A prospective randomised controlled trial - The ADAPT study
Presenter: Noelle Vrancken Peeters
Session: Lunch and Poster Display session
273P - Experiences and preferences about information on treatment (tx)-related side effects (SE) among patients (pts) with early breast cancer (EBC)
Presenter: Antonio Di Meglio
Session: Lunch and Poster Display session
274P - Efficacy of surgical gloves (SG) as compression therapy versus frozen gloves (FG) to prevent paclitaxel-induced peripheral neuropathy (PN): The trial ELEGANT
Presenter: Aurélia JOUREAU-CHABERT
Session: Lunch and Poster Display session
275P - Clinical and socioeconomic risk factors of prolonged opioid use after breast cancer: A Danish population-based study
Presenter: Kirsten Woolpert
Session: Lunch and Poster Display session
276P - Pitfalls and consequences of insufficient data recording of patient reported outcomes (PROs) in metastatic breast cancer trials
Presenter: Can Ünal
Session: Lunch and Poster Display session
277P - Descriptive analysis of hepatic safety for patients (pts) with HR+/HER2- breast cancer (BC) treated with ribociclib (RIB) + endocrine therapy (ET)
Presenter: Nadia Harbeck
Session: Lunch and Poster Display session